The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | The ALPINE trial shows improved outcomes with zanubrutinib versus ibrutinib in R/R CLL
Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the ALPINE trial (NCT03734016), comparing zanubrutinib to ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). The trial demonstrated an improved overall response rate (ORR) and progression-free survival (PFS) in the zanubrutinib arm, especially in high-risk patients with 17p deletions. Dr Brown highlights that these positive results encourage clinicians to incorporate zanubrutinib into clinical practice. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Loxo/Lilly, Pharmacyclics, Numab Therapeutics, Merck, Grifols Worldwide Operations, Kite, BeiGene, iOnctura, Alloplex Biotherapeutics, Hutchmed, Pfizer, Genentech/Roche, Abbvie, Acerta/AstraZeneca; Research Funding: Loxo/Lilly, TG Therapeutics, Gilead, BeiGene, iOnctura, SecuraBio, MEI Pharma.
